[go: up one dir, main page]

DK1350511T3 - Medicinsk sammensætning indeholdende aspirin - Google Patents

Medicinsk sammensætning indeholdende aspirin

Info

Publication number
DK1350511T3
DK1350511T3 DK01271850T DK01271850T DK1350511T3 DK 1350511 T3 DK1350511 T3 DK 1350511T3 DK 01271850 T DK01271850 T DK 01271850T DK 01271850 T DK01271850 T DK 01271850T DK 1350511 T3 DK1350511 T3 DK 1350511T3
Authority
DK
Denmark
Prior art keywords
composition containing
medicinal composition
pharmaceutical compositions
containing aspirin
aspirin
Prior art date
Application number
DK01271850T
Other languages
English (en)
Inventor
Fumitoshi Asai
Atsuhiro Sugidachi
Taketoshi Ogawa
Teruhiko Inoue
Original Assignee
Daiichi Sankyo Co Ltd
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18858878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1350511(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd, Ube Industries filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of DK1350511T3 publication Critical patent/DK1350511T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK01271850T 2000-12-25 2001-12-20 Medicinsk sammensætning indeholdende aspirin DK1350511T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000392983 2000-12-25
PCT/JP2001/011201 WO2002051412A1 (en) 2000-12-25 2001-12-20 Medicinal compositions containing aspirin

Publications (1)

Publication Number Publication Date
DK1350511T3 true DK1350511T3 (da) 2009-01-05

Family

ID=18858878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01271850T DK1350511T3 (da) 2000-12-25 2001-12-20 Medicinsk sammensætning indeholdende aspirin

Country Status (25)

Country Link
US (3) US20040024013A1 (da)
EP (1) EP1350511B1 (da)
KR (1) KR100692934B1 (da)
CN (1) CN100341506C (da)
AT (1) ATE407675T1 (da)
AU (1) AU2002217464B2 (da)
BR (1) BR0116531A (da)
CA (1) CA2432644C (da)
CY (1) CY1108626T1 (da)
CZ (1) CZ297570B6 (da)
DE (1) DE60135780D1 (da)
DK (1) DK1350511T3 (da)
ES (1) ES2311498T3 (da)
HU (1) HUP0400644A3 (da)
IL (2) IL156456A0 (da)
MX (1) MXPA03005770A (da)
NO (1) NO20032902D0 (da)
NZ (1) NZ526540A (da)
PL (1) PL206138B1 (da)
PT (1) PT1350511E (da)
RU (1) RU2262933C2 (da)
SK (1) SK287972B6 (da)
TW (1) TWI293249B (da)
WO (1) WO2002051412A1 (da)
ZA (1) ZA200304878B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298132B1 (en) * 2000-07-06 2006-11-22 Sankyo Company, Limited Hydropyridine derivative acid addition salts
CN100341506C (zh) 2000-12-25 2007-10-10 三共株式会社 含有阿斯匹林的药用组合物
JP2006525328A (ja) * 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー 心疾患の治療方法
CN100488163C (zh) * 2005-01-19 2009-05-13 华为技术有限公司 组播业务处理方法和系统
CN101198329A (zh) * 2005-06-17 2008-06-11 伊莱利利公司 普拉格雷给药方案
DE102005029612A1 (de) * 2005-06-23 2007-01-04 Hochschule Bremen Vorrichtung zum Erzeugen eines Panoramabildes
EP1940399A2 (en) * 2005-08-19 2008-07-09 Eli Lilly & Company Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases
EP2032521B1 (en) * 2006-06-27 2009-10-28 Sandoz AG New method for salt preparation
CA2672134C (en) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
US20090291138A1 (en) * 2006-12-07 2009-11-26 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
CN101594865A (zh) * 2006-12-07 2009-12-02 第一三共株式会社 含有低取代的羟基丙基纤维素的药物组合物
US20110201814A1 (en) * 2006-12-07 2011-08-18 Daiichi Sankyo Company Limited Method for producing solid preparation
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
JP5363307B2 (ja) * 2007-03-02 2013-12-11 第一三共株式会社 高純度のプラスグレル塩酸塩の製造方法
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
CN101177430A (zh) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
JP2011529859A (ja) 2008-08-02 2011-12-15 ルナン ファーマシューティカル グループ コーポレーション プラスグレル重硫酸塩及びその薬物組成物並びにその応用
DK3100728T3 (da) * 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme
CN102228691A (zh) * 2011-06-29 2011-11-02 北京阜康仁生物制药科技有限公司 阿司匹林和一种抗血小板药物的药物组合物
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
DK3107548T3 (da) 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2890240A (en) * 1956-03-28 1959-06-09 Monsanto Chemicals Aspirin crystallisation
US3235583A (en) * 1964-07-22 1966-02-15 Norwich Pharma Co Preparation of aspirin
US3890240A (en) * 1966-11-28 1975-06-17 Pitney Bowes Inc Toner compositions and methods for their preparation
FR2215948B1 (da) 1973-02-01 1976-05-14 Centre Etd Ind Pharma
FR2345150A2 (fr) 1975-08-06 1977-10-21 Centre Etd Ind Pharma Nouveaux derives de la thienopyridine, et leur application
FR2307538A1 (fr) * 1975-04-18 1976-11-12 Centre Etd Ind Pharma Nouveau medicament anti-agregant plaquettaire
FR2312247A1 (fr) 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
FR2358150A1 (fr) * 1976-07-13 1978-02-10 Parcor Nouvelles thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application
FR2376860A1 (fr) * 1977-01-07 1978-08-04 Parcor Tetrahydro-4,5,6,7 thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application therapeutique
GB1576511A (en) * 1977-03-29 1980-10-08 Parcor Thieno(2,3 - c) and (3,2 - c) pyridines process for their preparation and therapeutic applications thereof
GB2038625B (en) * 1978-12-29 1983-01-12 Parcor Therapeutic composition having an antithrombotic and antiblood-platelet-aggregating activity
CA1147658A (en) 1980-01-03 1983-06-07 Edouard Panak Therapeutic compositions having antithrombotic and anti-blood-platelet- aggregating activity
US4400384A (en) * 1980-10-06 1983-08-23 Sanofi, S.A. 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate and other novel salts thereof
US4321266A (en) * 1980-10-06 1982-03-23 Sanofi 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-C] pyridine
FR2495156A1 (fr) * 1980-11-28 1982-06-04 Sanofi Sa Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique
FR2528848A1 (fr) * 1982-06-16 1983-12-23 Sanofi Sa Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) * 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FR2596392B1 (fr) 1986-03-27 1988-08-05 Sanofi Sa Derives de l'acide a-(hydroxy-3 oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenylacetique, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2597102B1 (fr) 1986-04-14 1988-08-26 Sanofi Sa Derives de l'acide a-(hydroxy-7 tetrahydro-4,5,6,7 thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
ZA926784B (en) * 1991-09-09 1993-03-29 Sankyo Co Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation.
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CA2087743C (en) 1992-02-06 1999-04-27 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
EP0573975A1 (en) 1992-06-08 1993-12-15 Fuji Photo Film Co., Ltd. 2-alkoxycarbonyl-5-o-chlorobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine derivative and process for producing the same
DK0641770T3 (da) 1993-03-17 1998-06-02 Meiji Seika Co Hidtil ukendte forbindelser med blodpladeaggegationsinhiberende aktivitet
JPH06271582A (ja) 1993-03-18 1994-09-27 Fuji Photo Film Co Ltd ４，５，６，７−テトラヒドロチエノ〔３，２−ｃ〕ピリジン誘導体の製造方法
EP0785205B1 (en) * 1994-10-07 2002-04-17 Ube Industries, Ltd. 2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same
JP3564791B2 (ja) 1995-04-21 2004-09-15 宇部興産株式会社 α−アミノケトン類の製造方法
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IT1306980B1 (it) 1999-01-13 2001-10-11 Magneti Marelli Spa Gruppo motore-cambio di velocita', in particolare per motocicli.
CN1108798C (zh) * 1999-01-26 2003-05-21 广东药学院 一种治疗、预防血栓形成及中风的复方制剂及其制备方法
JP2000266780A (ja) 1999-03-18 2000-09-29 Matsushita Electric Ind Co Ltd プローブカードとそれを用いた検査装置
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311923B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
FR2792836B3 (fr) 1999-04-30 2001-07-27 Sanofi Sa Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1298132B1 (en) 2000-07-06 2006-11-22 Sankyo Company, Limited Hydropyridine derivative acid addition salts
JP4001199B2 (ja) 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
HUP0400651A2 (hu) * 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
CN100341506C (zh) 2000-12-25 2007-10-10 三共株式会社 含有阿斯匹林的药用组合物
US6670386B2 (en) * 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
KR20070052780A (ko) * 2004-09-21 2007-05-22 테바 파마슈티컬 인더스트리즈 리미티드 결정질 클로피도그렐 브롬산염 및 이의 제조 방법
DE112009000268T5 (de) * 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
DE202008003557U1 (de) 2008-03-13 2008-06-05 Riela - Getreidetechnik Karl-Heinz Knoop E.K. Schubwendetrockner mit Feuchte-Messeinrichtung
EP2112155B1 (en) 2008-04-25 2010-09-29 Sandoz AG Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
GB2469883A (en) 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
HU3745U (en) 2009-10-01 2010-03-29 Laszlo Borzan Disk guide device for target disk launcher or bowler equipments

Also Published As

Publication number Publication date
TWI293249B (en) 2008-02-11
SK287972B6 (sk) 2012-08-06
NO20032902L (no) 2003-06-24
RU2262933C2 (ru) 2005-10-27
IL156456A (en) 2006-12-10
DE60135780D1 (de) 2008-10-23
HK1056118A1 (en) 2004-02-06
PL206138B1 (pl) 2010-07-30
CY1108626T1 (el) 2014-04-09
KR20030065558A (ko) 2003-08-06
CZ297570B6 (cs) 2007-02-07
EP1350511A1 (en) 2003-10-08
CN1491109A (zh) 2004-04-21
NO20032902D0 (no) 2003-06-24
IL156456A0 (en) 2004-01-04
NZ526540A (en) 2004-11-26
BR0116531A (pt) 2004-02-25
PT1350511E (pt) 2008-10-28
SK7542003A3 (en) 2003-12-02
ZA200304878B (en) 2004-08-10
US20040024013A1 (en) 2004-02-05
MXPA03005770A (es) 2003-09-10
CA2432644C (en) 2013-07-23
ES2311498T3 (es) 2009-02-16
HUP0400644A3 (en) 2009-06-29
HUP0400644A2 (hu) 2004-06-28
PL363183A1 (en) 2004-11-15
CZ20031660A3 (cs) 2003-12-17
US8404703B2 (en) 2013-03-26
EP1350511B1 (en) 2008-09-10
WO2002051412A1 (en) 2002-07-04
EP1350511A4 (en) 2004-06-23
KR100692934B1 (ko) 2007-03-12
US20080108589A1 (en) 2008-05-08
US20070010499A1 (en) 2007-01-11
CA2432644A1 (en) 2002-07-04
ATE407675T1 (de) 2008-09-15
CN100341506C (zh) 2007-10-10
US8569325B2 (en) 2013-10-29
AU2002217464B2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
DK1350511T3 (da) Medicinsk sammensætning indeholdende aspirin
DK0816376T3 (da) Thrombininhibitorer som antikoagulante midler
EP1734041A3 (en) Platelet ADP receptor inhibitors
CY1110395T1 (el) Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
CA2219742A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
NO20034612L (no) 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
NL300385I1 (nl) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
SE9901573D0 (sv) New compounds
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
WO2003051838A3 (en) Protein kinase inhibitors
SE0002729D0 (sv) Novel compound form
DE69819539D1 (de) Antithrombotische mittel
PT1147105E (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares
SE9901572D0 (sv) New compounds
SE9902937D0 (sv) Pharmaceutical compositions
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
PT862433E (pt) Composicao farmaceutica espumante topica para o tratamento de dermatoses induzidas por pityrosporum oval
HRP20050815A2 (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
ATE315038T1 (de) Antibakterielle mittel